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The inherent biology of neural stem cells (NSCs) endows
them with capabilities that not only circumvent many of the
limitations of other gene transfer vehicles, but that enable a
variety of novel therapeutic strategies heretofore regarded
as beyond the purview of neural transplantation. Most neuro-
degenerative diseases are characterized not by discrete,
focal abnormalities but rather by extensive, multifocal, or
even global neuropathology. Such widely disseminated
lesions have not conventionally been regarded as amenable
to neural transplantation. However, the ability of NSCs to
engraft diffusely and become integral members of structures
throughout the host CNS, while also expressing therapeutic
molecules, may permit these cells to address that challenge.
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Introduction
Cell-based therapies such as neural transplantation have,
until recently, been reserved for focal or regionally
restricted neurologic diseases. These are best exemplified
by Parkinson’s disease,1–4 where the goal has been the
engraftment and enhanced survival of dopamine-produc-
ing cells within the striatum, or by forestalling degener-
ation of dopaminergic neurons within the substantia
nigra (SN). However, the pathologic lesions of most neur-
ogenetic diseases – indeed, most neurologic disorders –
are usually widely disseminated in the brain and spinal
cord and have not typically been regarded as within the
purview of neural transplantation. Such diseases include
not only the inherited neurodegenerative diseases of the
pediatric age group (eg lysosomal storage diseases, leu-
kodystrophies, inborn errors of metabolism, hypoxic-
ischemic encephalopathy), but also such adult maladies
as Alzheimer’s disease (AD), Huntington’s disease (HD),
multi-infarct dementia, multiple sclerosis (MS), amy-
otrophic lateral sclerosis (ALS), and brain tumors
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Intriguingly, while NSCs can be readily engineered to
express specified foreign genes, other intrinsic factors
appear to emanate spontaneously from NSCs and, in the
context of reciprocal donor–host signaling, seem to be cap-
able of neuroprotective and/or neuroregenerative functions.
Stem cells additionally have the appealing ability to ‘home
in’ on pathology, even over great distances. Such obser-
vations help to advance the idea that NSCs – as a prototype
for stem cells from other solid organs – might aid in recon-
structing the molecular and cellular milieu of maldeveloped
or damaged organs.
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(especially glioblastomas). Therapeutic approaches for
such ‘global’ problems have typically depended on phar-
macologic or genetic interventions. They have been
regarded as beyond the purview of cellular-mediated
approaches. Cell replacement therapies have largely been
limited to transplantation of somatic cells derived from
the hematopoietic system administered via bone marrow
transplantation (BMT). In the majority of these disorders,
such strategies have been unsatisfactory for treating the
CNS component of the disease.
The recognition that neural progenitor or stem cells, or
cells that model their behavior, might integrate appropri-
ately throughout the mammalian CNS following trans-
plantation (for example, Refs 5–9) has unveiled a new
role for neural transplantation and gene therapy and a
possible strategy for addressing the CNS manifestations
of diseases that heretofore had been refractory to inter-
vention. Multipotent neural stem cells (NSCs) are oper-
ationally defined by their ability to self-renew, to differ-
entiate into cells of all glial and neuronal lineages
throughout the neuraxis, and to populate developing or
degenerating CNS regions (reviewed in Refs 10–15). Thus
their use as graft material can be considered analogous
to hematopoietic stem cell-mediated reconstitution and
gene transfer.
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Limitations of various gene transfer and
cellular repair strategies for the CNS
A number of inherited metabolic diseases, in which a sin-
gle gene product is deficient, can be partially treated by
BMT or enzyme replacement. In many cases, such inter-
ventions have been successful in addressing peripheral
manifestations but have been disappointing in reversing
or forestalling damage to CNS because the blood–brain
barrier (BBB) restricts entry of therapeutic molecules
from the vascular compartment. BMT also usually
involves conditioning regimens such as irradiation, that
are deleterious to the developing CNS. Pharmacologic
agents for CNS disease administered systemically often
have erratic effects, transient efficacy, and undesirable
side-effects.
The delivery of gene products directly to the CNS
might circumvent these problems. Gene transfer may be
achieved by the direct delivery of genetic material to the
host’s own neural tissue. The vectors presently available,
however, are sometimes difficult to target in situ to the
specific neural cell types and regions most in need of cor-
rection. For example, retroviral vectors infect only mitotic
cells, which are less abundant in the post-developmental
CNS and often not the cells needing therapy. Although
encouraging progress is being made in the use of lenti-
and adeno-associated virus (AAV)-based vectors for
post-mitotic neural tissue, they do not often target the
widespread lesions and multiple cell types characteristic
of many neurogenetic diseases. Only cells in a relatively
spatially restricted area are typically corrected. AAV,
although possessing a wider distribution, may have a sel-
ectivity for neurons to the exclusion of oligodendrocytes
and astrocytes. The safety and efficacy in vivo of many of
these vectors remains to be established.
Alternatively, gene products may be imported into the
host CNS by the implantation of synthetic ‘pumps’, or
genetically modified donor cells that can reside within
the CNS to deliver exogenous factors to host cells. Geneti-
cally engineered non-neural cells (eg fibroblasts) can be
used for localized delivery of discrete molecules to the
CNS and can be implanted autologously.16,17 However,
this approach is limited to correction of disease only in
the vicinity of the graft and they lack the ability to incor-
porate widely into host cytoarchitecture in a functional
manner following implantation. Thus, essential circuits
may not be reformed and the regulated release of
important factors through feedback loops may be miss-
ing. For some substances and impairments, the unregu-
lated, inappropriate, excessive, or ectopic release may be
harmful to the host (for example, NGF16 and
dopamine17). The choice of vehicle for a particular disease
process may, therefore, need to be determined on an indi-
vidual basis by a better understanding of the pathobiol-
ogy and replacement needs underlying a particular
defect. Of note, down-regulation of neural gene
expression in engineered non-neural cells may leave
them ‘incapacitated’. However, donor tissue originating
from the brain may sustain expression of neural genes
longer. Low levels of normal neural cell products
expressed intrinsically by donor neural-derived cells may
enhance the therapeutic effects of such engineered cells.
Many neurogenetic diseases are characterized by the
degeneration of specific neural cell types or circuits.
These losses may be due to the presence of certain toxins
in the milieu, an insufficiency of various trophins in the
microenvironment, or to pathologic processes intrinsic to
the metabolic deficiency of the diseased cell. Therefore,
ideal grafts would not only provide exogenous thera-
peutic gene products, but would also effect repair of
damaged host brain by becoming integral components of
the host cytoarchitecture and circuitry. Indeed, one of the
major deficiencies for most extant gene therapy tech-
niques for neurodegenerative diseases is that they
involve inserting new genetic information on old neural
substrates that may have already become dysfunctional
or degenerated. The challenge is to create new substrates
on which these therapeutic genes can operate. Tissue-
derived from the CNS may also provide as yet unrecog-
nized endogenous neural-specific substances that are
beneficial to the host. It has already been recognized that
NSCs intrinsically produce a broad range of peptide neu-
rotrophic factors (eg GDNF, BDNF, NGF, NT-3, NT-
4/5).19
Mature or even young neurons derived from the CNS
would seem to be the ideal graft material. However, there
are restrictions on the types and ages of neurons that suc-
cessfully survive implantation in a functionally meaning-
ful way for prolonged periods. Primary neurons also
have limited usefulness as vehicles for stable gene trans-
fer since their limited mitotic capacity restricts their
ability to be expanded into adequate numbers for graft-
ing, as well as their ability to be transduced ex vivo by
retroviral vectors. Primary fetal neuronal tissue has his-
torically been the most successful donor tissue for CNS
grafting and has shown promise for the amelioration of
certain neurologic conditions (reviewed in Ref. 19). How-
ever, the use of fetal tissue involves significant concerns
including: the ready availability of sufficient amounts of
suitable disease-free material; ensuring survival of
desired cells in tissue which is typically heterogeneous
and contains non-neural cells; augmenting the expression
of biological molecules by donor fetal tissue; and limited
or very focal integration of the fetal graft into the host
brain.
Properties of NSCs useful for therapeutics
The recognition that NSCs propagated in culture could
be reimplanted into mammalian brain, where they could
reintegrate appropriately and stably express foreign
genes20,21 made this strategy an attractive alternative for
CNS gene therapy and repair. Numerous subsequent
studies over the past decade (reviewed in Ref. 15) reaf-
firmed that neural progenitors from many regions and
developmental stages could be maintained, perpetuated,
and passaged in vitro by a number of epigenetic and gen-
etic methods. Examples include the transduction of genes
interacting with cell cycle proteins (eg vmyc) and by
mitogen stimulation (eg EGF and/or bFGF).20–26 Some of
these methods may operate through common cellular
mechanisms. This speculation is supported by the obser-
vation that many progenitor cell lines behave similarly
in their ability to reintegrate into the CNS despite the fact
that they were generated by different methods, obtained
from various locations, and reimplanted into various
CNS regions. Some of these NSC lines appear sufficiently
plastic to participate in normal CNS development from
germinal zones of multiple regions along the neuraxis
and at multiple stages of development from embryo to
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vitro and in vivo behavior of some primary fetal and adult
neural cells,31–36 suggesting that insights gleaned from
these NSC lines may legitimately reflect the potential of
CNS progenitor or stem cells.
Some of the inherent biologic properties of NSCs may
circumvent some of the limitations of other techniques
for treating metabolic, degenerative, or other widespread
lesions in the brain. They are easy to administer (often
directly into the cerebral ventricles), are readily
engraftable, and circumvent the BBB. A preconditioning
regime is not required before administration (eg total
body irradiation) as is required for BMT. One important
property of NSCs is their apparent ability to develop into
integral cytoarchitectural components37of many regions
throughout the host brain as neurons, astrocytes, oligo-
dendrocytes, and even incompletely differentiated but
quiescent progenitors. Therefore, they may be able to
replace a range of missing or dysfunctional neural cell
types. A given NSC clone can give rise to multiple cell
types within the same region. This is important in the
likely situation where return of function may require the
reconstitution of the whole milieu of a given region – eg
not just the neurons but also the glia and support cells
required to nurture, detoxify and/or myelinate the neu-
rons. They appear to respond in vivo to neurogenic sig-
nals not only when they occur appropriately during
development, but even when induced at later stages by
certain neurodegenerative processes, eg during
apoptosis.21,38 NSCs may be attracted to regions of neuro-
degeneration in the young as well as in the aged.39–41
NSCs also appear to accommodate to the region of
engraftment, perhaps obviating the necessity for
obtaining donor cells from many specific CNS regions or
the imperative for precise targeting during reimplan-
tation. The cells might express certain genes of interest
intrinsically (for example, many neurotrophic factors), or
they can be engineered ex vivo to do so since they are
readily transduced by gene transfer vectors. These gene
products can be delivered to the host CNS in a direct,
immediate, and stable manner.5,8,40,42While NSCs can
migrate and integrate widely throughout the brain parti-
cularly well when implanted into germinal zones,
allowing reconstitution of enzyme or cellular deficiencies
in a global manner,5,8,42 this extensive migratory ability
is present even in the parenchyma of the diseased
adult5,40 and aged43 brain. Despite their extensive plas-
ticity, NSCs never give rise to cell types inappropriate to
the brain (eg muscle, bone, teeth) or yield neoplasms.
Testing the therapeutic potential of NSCs
These attributes of NSCs may provide multiple strategies
for treating a range of CNS dysfunction. As proof-of-prin-
ciple, they were first tested experimentally in mouse
models of genetically based neurodegeneration. Their
ability to mediate gene therapy was affirmed in a model
of the neurogenetic lysosomal storage disease (LSD),
mucopolysaccharidosis type VII (MPS VII).5 Mice homo-
zygous for a frameshift mutation in the -glucuronidase
gene are devoid of the secreted enzyme -glucuronidase
(GUSB). The enzymatic deficiency results in lysosomal
accumulation of undegraded glycosaminoglycans in the
brain and other tissues, causing a fatal progressive
degenerative disorder. Treatments for MPS VII and most
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other LSDs are designed to provide a source of normal
enzyme for uptake by diseased cells, a process termed
‘cross-correction’.44 The goal of ex vivo gene therapy is to
engineer donor cells to express the normal GUSB protein
for export to other host cells. The engraftment and inte-
gration of GUSB overexpressing NSCs throughout the
newborn MPS VII mutant brain succeeded in providing a
sustained, lifelong, widespread source of cross-correcting
enzyme in a manner not previously achieved.5
A rapid intraventricular injection technique was
devised for the diffuse engraftment of the NSCs. Injecting
the progenitors into the cerebral ventricles presumably
allowed them to gain access to most of the subventricular
germinal zone (SVZ), as well as to networks of cerebral
vasculature, along the surface of which they would also
migrate. This approach worked equally well in the fetus
where donor NSCs gained access to the ventricular ger-
minal zone (VZ),42 migrating into the parenchyma within
24–48 h. This engraftment technique, exploiting many of
the inherent properties of NSCs, permitted missing gene
products to be delivered without disturbing other neuro-
biological processes and suggested a strategy for gene
therapy of a class of neurogenetic diseases that, hereto-
fore, had not been adequately treated (Figure 1a). While
MPS VII may be regarded as ‘uncommon’, the broad cat-
egory of diseases that it models (neurogenetic conditions)
afflicts as many as 1 in 1500 children and serves as a
model for many adult neurodegenerative processes of
genetic origin (AD, for example, could broadly fall into
this category). Therapy instituted early in life might
arrest disease progression and prevent irreversible CNS
alterations. Even in the adult brain, there are routes of
relatively extensive migration followed by both endogen-
ous and transplanted NSCs.45,46 If injected into the cer-
ebral ventricles of normal adult mice, NSCs (including
those expressing transgenes) will integrate into the SVZ
and migrate long distances, eg to the olfactory bulb,
where they differentiate into interneurons, and occasion-
ally into subcortical parenchyma where they become
glia.6,27,28,47,48 Although these migratory paths are still
relatively restricted and stereotyped compared with that
seen in the fetal or newborn brain, in the degenerating,
abnormal, or injured adult brain (as discussed below),
migration by foreign gene-expressing NSCs can be exten-
sive and directed specifically to regions of pathology, a
phenomenon observed to date with stroke, head injury,
dopaminergic dysfunction, brain tumors and amyloid
plaques.
The therapeutic paradigm described above can be
extended to other untreatable neurodegenerative diseases
characterized by an absence of gene products and/or the
accumulation of toxic metabolites. In almost all cases,
NSCs, because they are normal cells, constitutively
express normal amounts of the particular enzyme in
question. The extent to which this amount needs to be
augmented may vary from model to model and enzyme
to enzyme. Reassuringly, in most inherited metabolic dis-
ease, the amount of enzyme required to restore normal
metabolism and forestall CNS disease may be quite
small. It is significant to note that, while the histograms
in Figure 1b illustrate the widespread distribution of a
lysosomal enzyme, they could similarly reflect the NSC-
mediated distribution of other diffusible (eg synthetic
enzymes, neurotrophins, viral vectors)49,50 and non-dif-
fusible (eg myelin, extracellular matrix) factors, as well as
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the distribution of ‘replacement’ neural cells (see section
below). For example, neural progenitors and stem cells
have been used for the local expression of NT-3 within
the rat spinal cord,51,52 NGF and BDNF within the sep-
tum,53,54 and tyrosine hydroxylase55,56 and Bcl-257 and
GDNF58 to the striatum. These earlier studies helped to
advance the idea that NSCs – as a prototype for stem
cells from any solid organ – might aid in reconstructing
both the molecules as well as the cells of a maldeveloped
or damaged organ. A further complexity, however, is the
recognition that the same NSC may not be able to be
engineered to express certain neurotrophic agents simul-
taneously because they may be processed antagon-
istically within the cell and/or within the environment.
Therefore a greater knowledge of the NSC processing of
certain molecules is a prerequisite.18
Replacing more than genes: cells, myelin,
extracellular matrix
Many neurologic diseases, even those that can be ameli-
orated by replacement of a gene product, are charac-
Figure 1 Widespread engraftment of NSCs expressing GUSB throughout
the brain of the MPS VII mouse (adapted from Ref. 5). (a) Brain of a
mature MPS VII mouse after receiving a neonatal intraventricular trans-
plant of murine NSCs expressing GUSB. Donor NSC-derived cells, ident-
ified by their X-gal histochemical reaction (blue precipitate) for expression
of the LacZ marker gene, have engrafted throughout the recipient mutant
brain. Representative coronal sections – placed at their appropriate level
by computer – show these cells to span the rostral-caudal expanse of the
brain. (b) Distribution of GUSB enzymatic activity throughout brains of
MPS VII NSC transplant recipients. Serial sections were collected from
throughout the brains of transplant recipients and assayed for GUSB
activity. Sections were pooled to reflect the activity present within the
regions demarcated in the schematic. The regions were defined by anatom-
ical landmarks in the anterior-to-posterior plane to permit comparison
among animals. The mean levels of GUSB activity for each region (n = 17)
are presented as the percentage of average normal levels for each region.
Untreated MPS VII mice show no GUSB activity biochemically or histo-
chemically. Enzyme activity of 2% of normal is corrective based on data
from liver and spleen. (c) Decreased lysosomal storage in a treated MPS
VII mouse brain at 8 months of age. (A) Extensive vacuolation rep-
resenting distended lysosomes (arrowheads) in both neurons and glia in
the neocortex of an 8-month-old, untransplanted control MPS VII mouse.
(B) Decrease in lysosomal storage in the cortex of an MPS VII mouse
treated at birth from a region analogous to the untreated control section
in (A). The other regions of this animal’s brain showed a similar decrease
in storage compared with untreated, age-matched mutants in regions
where GUSB was expressed. Scale bars, 21 m.
terized by the degeneration of cells or circuits. These
cytoarchitectural components may need to be replaced in
a functional manner and be resistant to residual toxic
processes. One reassuring insight from the classic fetal
transplant literature is that even modest anatomical
reconstruction may sometimes have an unexpectedly
beneficial functional effect.18 Early experiments with NSC
clones in various rodent mutants and injury models have
provided evidence that NSCs may be able to replace
some degenerated or dysfunctional neural cells. In the
meander tail (mea) mutant mouse, which is characterized
by a deficiency of cerebellar granule cell (GC) neurons,
NSCs, implanted at birth, were capable of ‘repopulating’
large portions of the GC-poor internal granular layer
(IGL) with neurons59 (a phenomenon that was sub-
sequently duplicated with human NSCs.6 A pivotal
observation to emerge from this work, with implications
for fundamental stem cell biology, was that cells with the
potential for multiple fates will ‘shift’ their differentiation
to compensate for a deficiency in a particular cell type.
As compared with their fate in normal cerebella, a
majority of these donor NSCs in GC-deficient regions
pursued a GC phenotype in preference to other potential
phenotypes, suggesting a ‘push’ on undifferentiated,
multipotent NSCs towards repletion of the ‘unmet’
quota. This work presented a possible developmental
mechanism with therapeutic value. Indeed, in the typi-
cally ‘non-neurogenic’ milieu of the adult neocortex, it
was learned that NSCs would ‘choose’ to differentiate
into neurons under conditions where host neurons were
experimentally eliminated by a targeted apoptotic pro-
cess.21The neuronal phenotype assumed by these NSCs
suggested that this circumscribed region of degeneration
created a microenvironment permissive or instructive for
a neuronal fate choice, likely through reactivation of
signals ordinarily available only during embryonic
corticogenesis.
Preliminary work in another mutant, the reeler (rl)
mouse, has suggested that NSCs may not only replace
developmentally impaired or degenerating cells, but may
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ture, particularly those characterized by deficiencies in
extracellular matrix (ECM). The laminar assignment of
neurons in rl brain is abnormal due to a mutation in a
gene encoding the secreted ECM molecule, Reelin. NSCs,
implanted at birth into the defective developing rl CB,
appeared not only to replace missing GCs, but also to
promote a more wild-type laminated appearance in
engrafted regions by ‘rescuing’ aspects of the abnormal
migration, positioning, and survival of host neurons most
likely by providing molecules (including Reelin) at the
cell surface to guide proper histogenesis. These findings
suggested a possible NSC-based strategy for the gene
therapy of CNS diseases characterized by abnormal
cellular migration, lamination and cytoarchitectural
arrangement.
White matter disease as a model system
It was hypothesized that the techniques described for the
widespread engraftment of NSCs for gene replacement
could be extended to the remediation of other types of
diffuse neuropathologies requiring other kinds of inter-
ventions. Mutants characterized by CNS-wide white mat-
ter disease provided ideal models for testing whether
NSCs might be useful for widespread cell replacement.8
The oligodendroglia of the dysmyelinated shiverer (shi)
mouse are dysfunctional because they lack myelin basic
protein (MBP) which is essential for proper myelination.
Therapeutic intervention, therefore, requires widespread
replacement with oligodendrocytes expressing MBP.
NSCs transplanted at birth – employing the same intra-
cerebroventricular implantation technique devised for
diffuse engraftment of enzyme-expressing NSCs to treat
global metabolic lesions – resulted in widespread
engraftment throughout the shi brain (Figure 2a) with
repletion of significant amounts of MBP (Figure 2b).
Accordingly, of the many donor-derived oligodendroglia
(NSCs indeed ‘shifted’ to yield a higher proportion of
such cells), a subgroup myelinated up to 52% of host neu-
ronal processes with better compacted myelin (Figure 2c).
Some animals experienced a decrease in their sympto-
matic tremor (Figure 2d).8 Therefore, ‘global’ cell replace-
ment seems feasible for some pathologies if cells with
stem-like features are employed. More specifically, the
ability of NSCs to generate myelinating cells is important
because disordered myelination plays a critical role in
many genetic and acquired (injury, infectious) neurodeg-
enerative processes. Oligodendroglial pathology is
prominent in stroke, spinal cord injury, head trauma,
ischemia and may account for a significant proportion of
the neurologic handicap seen in asphyxiated and prema-
ture newborns. More broadly, complementation studies
in mutants such as those described above, help support
an NSC-based approach – whether with exogenous cells
or with mobilized endogenous ones – for compensating
for neurodevelopmental problems of many etiologies.
Accordingly, the approach employed in shi has been
extended to other demyelinated and oligodendrocyte-
deficient mutants. Loss of galactocerebrosidase- (GALC)
activity results in the accumulation in oligodendrocytes
of psychosine, a toxic glycolipid. The resultant disease in
humans is Krabbe’s or globoid cell leukodystrophy
(GLD). Children afflicted with GLD exhibit inexorable
psychomotor deterioration and early death, presumably
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as a result of dysfunctional and ultimately degenerated
oligodendrocytes with loss of myelin. The twitcher (twi)
mouse is an authentic model of GLD. In preliminary
studies, murine NSCs have been transplanted into the
brains of both neonatal and symptomatic juvenile twi
mice. The NSCs engrafted exuberantly throughout the
brains, particularly in newborns (as per Figures 1 and 2),
and differentiated extensively into healthy oligodendro-
cytes that elaborated normal-appearing myelin. Each
NSC-derived oligodendrocyte appeared to remyelinate
up to 30–50 host axons. Interestingly, unlike in shi, cell
replacement even to this extent and magnitude was,
nevertheless, unable to remediate symptoms or prolong
the life of the twi mouse. This observation became
instructive, however, as to how one might need to treat
some complex global neurogenetic diseases. Although,
engraftment of these unengineered NSCs did not appear
to result in symptomatic improvement, the fact remained
that exogenous NSCs could survive and differentiate into
myelinating oligodendrocytes within the twi environ-
ment. There is a prevailing belief that GLD pathophysiol-
ogy is related to the toxic psychosine-filled environment,
one that kills not only host cells, but theoretically any
new cells placed into that milieu, hence dooming any
attempts at cell replacement. The twi brain, however, was
not inherently non-permissive. One could hypothesize
that the absence of GalC not only permits the toxic build-
up of psychosine, but predisposes Krabbe neural cells
(especially oligodendrocytes) to be more vulnerable to
that toxicity in a way that wild-type NSCs may not. Pilot
experiments were, therefore, performed in which the
NSCs that had differentiated into oligodendrocytes in the
twi brain, were exposed in culture to increasing concen-
trations of psychosine, particularly concentrations that
were inimical to Krabbe cells. The NSCs proved to be
resistant to those toxic effects. As the concentrations were
further increased, the NSCs did begin to show some tox-
icity. However, interestingly, when populations of those
same NSCs were engineered to overexpress GalC
(enough to cross-correct fibroblasts from Krabbe patients
in culture) they were now no longer affected by that and
even higher psychosine concentrations in vitro. Although
preliminary, these results suggest a number of important
points regarding the use of cellular therapies against
complex degenerative diseases, such as GLD. A compo-
nent of treatment will likely not only be cell replacement,
but also cross-correction of host cells to overexpress GalC
and hence be more resistant. While oligodendrocyte
replacement alone is not a sufficient treatment for GLD
(even when extensive), the replacement of both cells and
molecules – eg with NSCs that can both become oligo-
dendrocytes and be pumps for GalC remains a promising
basis for a multidisciplinary strategy. Additionally, it is
not unexpected that the present experimental design did
not result in prolonged lives in animals with system-wide
disease (ie cerebellar, spinal and peripheral, as well as
intracerebral; extracranial as well as intracranial). Inter-
ventions may call for implantation of NSCs at multiple
locations, as well as at multiple time points in the evol-
ution of the disease, beginning, if possible, presympto-
matically and continuing after disease is established.
Interventions will likely need to combine NSC implan-
tation in the brain with strategies to address extracranial
manifestations (eg BMT) that together may prolong life.
Most neurological disease is complex in this way and will
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likely require multifaceted approaches, perhaps with
NSCs serving as the ‘glue’. Importantly, we learn, how-
ever, that NSCs may be useful even in cell non-auton-
omous diseases if the NSCs are intrinsically resistant to
or neutralizing of the toxic milieu – or can be engineered
to be so.
‘Homing in’ on pathology from even long
distances
It is tempting to speculate that the ability of NSCs to pur-
sue alternative differentiation paths in response to certain
types of neurodegeneration21,59 and their ability to
migrate and express foreign genes can be targeted selec-
tively to the regions most in need. Evidence (some pub-
lished, some preliminary) in various models suggests that
this may be feasible: during phases of active neurodegen-
eration, as yet unidentified factors seem to be transiently
elaborated to which NSCs may ‘home’.
Hypoxic-ischemic brain injury
In pilot studies, when NSCs are transplanted into brains
of young mice subjected to unilateral hypoxic-ischemic
(HI) brain injury (a model for cerebral palsy), donor-
derived cells migrated preferentially to and integrated
extensively within the large ischemic areas that typically
spanned the injured hemisphere. A subpopulation of
donor NSCs, particularly in the penumbra of the infarct,
‘shifted’ their differentiation fate towards neurons and
oligodendrocytes, the neural cell types typically damaged
following asphyxia/stroke. Furthermore, there appeared
to be an optimal window of time following injury (3–7
days) during which signals were elaborated within the
degenerating region and to which NSCs responded with
migration and reconstitution of lost neural cells. (Similar
observations have been noted by Hodges et al60).
Because engrafted donor-derived cells continue to
express their LacZ reporter gene, it appeared feasible that
desired differentiation, neurite outgrowth, and connectiv-
ity of both host and donor-derived cells might be
enhanced if donor NSCs were genetically manipulated ex
vivo to express certain trophins, cytokines, or other fac-
tors. When, in pilot studies, a subclone of the same
murine NSCs were engineered via retroviral transduction
to overexpress neurotrophin-3 (NT-3) (known to play a
role in inducing neuronal differentiation) and then
implanted into asphyxiated mouse brains, the percentage
of donor-derived neurons increased from 5% (in the
above described experiments) to 20% in the infarction
cavity and up to >80% in the penumbra. It seemed likely
that the NSCs (which bear a functional trkC receptor)
were producing a factor that worked in an
autocrine/paracrine fashion. While it remains far from
clear that one would even desire so many neurons, this
observation suggests that a naturally occurring NSC-
based process in a degenerative environment can be aug-
mented via genetic engineering. Furthermore, migratory
NSCs may be capable of simultaneous gene therapy and
cell replacement during the same transplantation pro-
cedure in the same recipient.
Brain tumors
Another dramatic example of using NSCs as gene deliv-
ery vehicles that home in on pathology is illustrated by
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Figure 2 ‘Global’ cell replacement is feasible via NSC transplantation: evidence from the dysmyelinated shiverer (shi) mouse brain (modified from Ref.
8). (a) NSCs engraft extensively throughout the shi dysmyelinated brain, including within white tracts, and differentiate into oligodendrocytes. LacZ-
expressing, -galactosidase (gal)-producing NSCs were transplanted into the cerebral ventricles of newborn shi mutants and analyzed systematically
at intervals between 2and 8 weeks following engraftment. Coronal sections through the shi brain at adulthood demonstrated widely disseminated inte-
gration of blue Xgal+ donor-derived cells throughout the neuraxis, similar to the pattern seen in Figure 1a in the MPS VII mutant mouse. Donor-
derived cells in the shi mouse brain are shown at higher magnification and greater detail in (A–D). (A, B) Donor-derived Xgal+ cells in representative
sections through the corpus callosum possessed characteristic oligodendroglial features (small, round or polygonal cell bodies with multiple fine processes
oriented in the direction of the neural fiber tracts). (C) Close-up of a representative donor-derived anti-gal immunoreactive oligodendrocyte (arrow)
extending multiple processes towards and beginning to enwrap large adjacent axonal bundles (‘a’) viewed on end in a section through the corpus
callosum. That cells such as those in panels A–C (and in b(B–D) were oligodendroglia was confirmed by the representative electron micrograph in panel
D (and in c) demonstrating their defining ultrastructural features (see Ref. 8). A donor-derived Xgal+ oligodendrocyte (‘LO’) can be distinguished by
the electron dense Xgal precipitate that is typically localized to the nuclear membrane (arrow), ER (arrowhead) and other cytoplasmic organelles. The
area indicated by the arrowhead is magnified in the inset to demonstrate the unique crystalline nature of individual precipitate particles. (b) MBP
expression in mature transplanted and control brains. (A) Western analysis for MBP in whole brain lysates. The brains of three representative trans-
planted shi mutants (lanes 2–4) expressed MBP at levels close to that of an age-matched unaffected mouse (lane 1, positive control), and significantly
greater than the amounts seen in untransplanted (lanes 7, 8, negative control) or unengrafted (lanes 5, 6, negative control) age-matched shi mutants.
(Identical total protein amounts were loaded in each lane.) (B–D) Immunocytochemical analysis for MBP. (B) The brain of a mature unaffected mouse
was immunoreactive to an antibody to MBP (revealed with a Texas Red-conjugated secondary antibody). (C, D) Age-matched engrafted brains from
shi mice similarly showed immunoreactivity. Because untransplanted shi brains lack MBP. MBP immunoreactivity has also classically been a marker
for normal donor-derived oligodendrocytes in transplant paradigms. (c) NSC-derived ‘replacement’ oligodendrocytes are capable of myelination of shi
axons. In regions of MBP-expressing NSC engraftment, shi neuronal processes became enwrapped by thick, better compacted myelin. (A) At 2 weeks
post-transplant, a representative donor-derived, labeled oligodendrocyte (‘LO’) (recognized by extensive Xgal precipitate (‘p’) in the nuclear membrane,
cytoplasmic organelles, and processes) was extending processes (a representative one is delineated by arrowheads) to host neurites, and was beginning
to ensheathe them with myelin (‘m’). (B) If engrafted shi regions, such as that in (A), were followed over time (eg to 4 weeks of age as pictured here),
the myelin began to appear healthier, thicker and better compacted (examples indicated by arrows) than that in age-matched untransplanted control
mutants. (C) By 6 weeks post-transplant, these matured into even thicker wraps; ~40% of host axons were ensheathed by myelin (a higher power view
of a representative axon is illustrated in panel C) that was dramatically thicker and better compacted than that of shi myelin (an example of which is
shown in panel D (black arrowhead) from an unengrafted region of an otherwise successfully engrafted shi brain). In panel C, white arrowheads indicate
representative regions of myelin that are magnified in the adjacent insets; MDLs are evident. (d) Functional and behavioral assessment of transplanted
shi mutants and controls. The shi mutation is characterized by the onset of tremor and a ‘shivering gait’ by the 2nd–3rd postnatal week. The degree
of motor dysfunction in animals was gauged in two ways: (1) by blindly scoring periods of standardized videotaped cage behavior of experimental and
control animals; and (2) by measuring the amplitude of tail displacement from the body’s rostral-caudal axis (an objective, quantifiable index of tremor).
Video freeze-frames of representative unengrafted and successfully engrafted shi mice are seen in panels A and B, respectively. The whole body tremor
and ataxic movement observed in the unengrafted symptomatic animal (A) causes the frame to blur, a contrast with the well-focused frame of the
asymptomatic transplanted shi mouse (B). Sixty percent of transplanted mutants showed nearly normal-appearing behavior as in panel B and attained
scores that were not significantly different from normal controls (see Ref. 8 for details). Panels C and D depict the manner in which whole body tremor
was mirrored by the amplitude of tail displacement (hatched gray arrow in panel C) measured perpendicularly from a line drawn in the direction of
the animal’s movement (solid gray arrow, represents the body’s long axis). Measurements were made by permitting a mouse, whose tail had been dipped
in India ink, to move freely in a straight line on a sheet of graph paper as shown. Large degrees of tremor cause the tail to make widely divergent ink
marks away from the midline, representing the body’s axis (C). Absence of tremor allows the tail to make long, straight, uninterrupted ink lines on the
paper congruent with the body’s axis (D). The distance between points of maximal tail displacement from the axis was measured and averaged for
transplanted and untransplanted shi mutants and for unaffected controls (hatched gray arrow). Panel C shows data from a poorly engrafted mutant
that did not improve with respect to tremor, while panel D reveals lack of tail displacement in a successfully engrafted asymptomatic mutant. Overall,
64% of transplanted shi mice examined displayed at least a 50% decrement in the degree of tremor or ‘shiver’. Several showed 0 displacement (see Ref.
8 for details).
their use against brain tumors. One of the impediments
to the treatment of such tumors as gliomas has been the
degree to which they expand, infiltrate surrounding
tissue, and migrate widely into normal brain, usually ren-
dering them ‘elusive’ to effective resection, irradiation,
chemotherapy, or gene therapy. Aboody et al40 (Figure 3)
demonstrated that migratory murine and human NSCs,
when implanted into intracranial gliomas in adult rod-
ents, distributed quickly and extensively throughout the
tumor bed (Figure 3aA) and migrated uniquely in juxta-
position to aggressively advancing tumor cells, while
continuing to stably express a foreign gene (Figure
3aB,C). The NSCs ‘surrounded’ the invading tumor bor-
der while ‘chasing down’ migrating infiltrating tumor
cells. Furthermore, when implanted intracranially at dis-
tant sites from the tumor bed in adult brain (eg into nor-
mal tissue (Figure 3bA,B), into the contralateral hemi-
sphere (Figure 3bC–H), or into the cerebral ventricles
(Figure 3bI,J), the donor NSCs crossed from one hemi-
sphere to the other, migrating through normal tissue to
the tumor on the opposite side, as if ‘drawn’ to and tar-
geting tumor cells. The NSCs appeared to be attracted
by either factors elaborated by tumors or by the tissue
destruction they rendered. NSCs could deliver a thera-
Gene Therapy
peutically relevant molecule – the oncolysis-promoting
enzyme cytosine deaminase – such that in vitro (Figure
4a) and in vivo (Figure 4b) a dramatic reduction in tumor
cell burden resulted. These data suggested the adjunctive
use of inherently migratory NSCs as a delivery vehicle
for more effectively targeting a wide variety of thera-
peutic genes and vectors to refractory, migratory, invas-
ive brain tumor cells. More broadly, they suggested that
NSC migration could be extensive, even in the adult
brain and along non-stereotypical routes, if pathology (as
modeled here by tumor) is present.
Amyloid plaques
More recently this notion has been extended in prelimi-
nary studies by Tate et al in our group,61 to address
lesions present in an adult animal model of AD-like path-
ology. The widespread amyloid deposits characteristic of
AD make it difficult to address with conventional graft-
ing approaches (for the potential replacement of dead or
dying neurons) or with traditional gene delivery vectors
(for molecular therapy). While the signals that stimulate
migration of NSCs are not yet identified, inflammatory
molecules are among the likely candidates. Tate pre-
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viously demonstrated that chronically infused human
amyloid will cause an inflammatory response in the rat
brain. In preliminary studies, Tate et al61 observed that
murine NSCs placed in the opposite lateral ventricle will
migrate to and surround areas of amyloid infusion. Pilot
studies in transgenic mouse models of AD (harboring a
similarly inflamed brain) suggest a similar tropism of
foreign gene-expressing NSCs for amyloid depositions.
NSCs may, therefore, play a role in the delivery of thera-
peutic molecules in adult global degenerative diseases
like AD. (It is not yet known whether they can similarly
replace neural cells that die in such diseases.)
Reciprocal NSC–host interactions and
augmenting this dynamic
While most work to date in stem cell biology has focused
on the concept that the host CNS environment – as it
changes over the course of development and aging or as
it is altered by injury or degeneration – influences or
instructs the stem cell, Ourednik et al41have accumulated
preliminary data suggesting that communication also
occurs in a reciprocal fashion: the NSC inherently
expresses genes that signal and instruct the host CNS.
This speculation derives in part from an interesting
observation following the implantation of murine NSCs
unilaterally into the SN of aged mice that, 1 month pre-
viously, had received repetitive systemic administrations
of high-dose MPTP, a neurotoxin that produces a persist-
ent impairment (though not death) of mesencephalic
dopaminergic (DA) neurons and their striatal projections
(similar to a dysfunction seen in the aging brain).41 Uni-
laterally implanted NSCs not only migrated and inte-
grated extensively within both hemispheres but were
associated with dramatic reconstitution of tyrosine
hydroxylase (TH) and dopamine transporter expression
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Figure 3 NSCs display extensive tropism for pathology in the adult brain: evidence from intracranial gliomas (modified from Ref. 32) (a) NSCs migrate
extensively throughout a brain tumor mass in vivo and ‘trail’ advancing tumor cells. Paradigm 1, in which NSCs are implanted directly into an
established experimental intracranial glioblastoma, is illustrated schematically. (A) The virulent and aggressively invasive CNS-1 glioblastoma cell line,
used to create the tumor, has been labeled ex vivo by transduction (via a retroviral vector) with green fluorescent protein (GFP) cDNA, allowing those
cells to fluoresce green (enhanced when revealed by an anti-GFP antibody). The NSCs stably express LacZ and produce -galactosidase (gal), allowing
them to be visualized as red (by anti-gal immunocytochemistry under fluorescence microscopy) or as blue (by Xgal histochemistry under light
microscopy). This panel, processed for double immunofluorescence using an anti-ßgal antibody (NSCs, red) and an anti-GFP antibody (glioblastoma
cells, green), shows a section of brain (under low power) from an adult nude mouse killed 10 days after NSC injection into the CNS-1 glioblastoma;
arrowheads demarcate approximate edges of the tumor mass where it interfaces with normal tissue. Donor red gal+ NSCs can be seen extensively
distributed throughout the mass, interspersed among the green tumor cells. This degree of interspersion by NSCs occurs within 48 h following injection.
Interestingly, while NSCs have extensively migrated and distributed themselves within the mass, they largely stop at the junction between tumor and
normal tissue except where a tumor cell is infiltrating normal tissue; then NSCs appear to ‘follow’ the invading tumor cell into surrounding tissue.
This ‘trailing’ of individual glioblastoma cells migrating away from the main tumor bed is examined in greater detail in panels B and C. (B) High
power view, under fluorescence microscopy, of single migrating infiltrating GFP+ tumor cells (green) in apposition to gal+ NSCs (red) (white arrow).
In a similar and perhaps even more impressive demonstration, the section in panel C is co-stained with Xgal (allowing the LacZ-expressing NSCs to
stain blue, arrow) and with neutral red (allowing the elongated glioblastoma cells to stain dark red. The blue NSC is in direct juxtaposition to a single
migrating, invading neutral red+, spindle-shaped tumor cell (arrow), the NSC ‘riding’ the glioma cell in ‘piggy-back’ fashion. Scale bars: [C] 60 m.
(b) NSCs implanted at various intracranial sites distant from main tumor bed migrate through normal adult tissue towards glioblastoma cells. (A, B)
Same hemisphere (paradigm 2): Shown here is a section through the tumor from an adult nude mouse 6 days following NSC implantation caudal to
tumor. In panel A (as per the schematic) a coned down view of a tumor populated as pictured under low power in a(A), note Xgal+ blue NSCs
interspersed among dark neutral red+ tumor cells. (B) High power view of NSCs in juxtaposition to islands of tumor cells. (C–H) Contralateral
hemisphere (paradigm 3): (C–E) As indicated on the schematic, these panels are views through the corpus callosum (‘c’) where ßgal+ immunopositive
NSCs (red cells, arrows) are seen migrating from their site of implantation on one side of the brain towards tumor on the other. Two representative
NSCs indicated by arrows in panel C are viewed at higher magnification in panels D and E, respectively, to visualize the classic elongated morphology
and leading process of a migrating neural progenitor oriented towards its target. In panel F, ßgal+ NSCs (red) are ‘homing in’ on the GFP+ tumor
(green) having migrated from the other hemisphere. In panel G, and magnified further in panel H, the Xgal+ blue NSCs (arrows) have now actually
entered the neutral red+ tumor (arrowheads) from the opposite hemisphere. (I, J) Intraventricular (paradigm 4): Shown here is a section through the
brain tumor of an adult nude mouse 6 days following NSC injection into the contralateral cerebral ventricle. In panel I, as per the schematic, blue
Xgal+ NSCs are distributed within the neutral red+ main tumor bed (edge delineated by arrowheads). At higher power in panel J, the NSCs are in
juxtaposition to migrating islands of red glioblastoma cells. Fibroblast control cells never migrated from their injection site in any paradigm. All Xgal-
positivity was corroborated by anti-gal immunoreactivity. Scale bar: (A): 20 m, and applies to panel C; (B): 8 m, and is 14 m in panels D and
E, 30 m in panels F and G, 15 m in panel H, 20 m in panel I, and 15 m in panel J.
bilaterally throughout the aged mesostriatal system.
While there was spontaneous conversion of NSCs to TH+
cells in DA-depleted areas, and while TH+ cells of donor-
origin contributed to nigral reconstitution, the majority
(~80–90%) of TH+ cells in the ‘reconstituted SN’ were
actually host cells ‘rescued’ presumably by constitutively
produced NSC-derived factors.
While the mechanism underlying this inherent NSC-
mediated protection or activation of a host regenerative
capacity remains uncertain, one mode is likely to be the
production by NSCs of trophic and tropic agents. NSCs
constitutively produce a broad range of peptide neuro-
trophic factors (including NT-3, NT-4/5, NGF, BDNF,
GDNF), adhesion molecules (eg L1), ECMs (eg reelin),
and lysosomal enzymes. In the example above, it was
interesting to note that, intermixed among NSCs that had
differentiated into TH+ neurons, was a larger subpopul-
ation of clonally related undifferentiated or glial-differen-
tiated donor-derived cells that intrinsically expressed
GDNF (among other peptides), a molecule known to be
neuroprotective of DA neurons. The broader implications
for CNS repair are that host structures may benefit not
only from NSC-derived replacement of missing neurons
but also from the ‘chaperone’ effect of
undifferentiated/glial-differentiated NSCs equally neces-
sary for promoting optimal reconstitution. While NSCs
have been touted for cell and gene therapy, these findings
suggest a third mechanism by which therapeutic out-
comes might be achieved: an inherent capacity of NSCs
to create host environments sufficiently rich in trophic
and/or neuroprotective support to promote the recovery
of damaged endogenous cells. If insufficient on their
own, these effects can likely be augmented.
Gene Therapy
Human NSCs
The identification of human NSCs (hNSCs)6,48,62–65
seemed to vouchsafe the conservation of certain neurode-
velopmental principles – initially gleaned from rodents –
to the human CNS. Stem cell-based strategies, therefore,
seemed a reasonable consideration for human neuro-
degenerative conditions.
Lines of engraftable hNSCs have been isolated from
normal human fetuses (ideally from the ventricular zone)
that, in many ways emulate their rodent counterparts
(reviewed in Refs 11 and 13) (albeit with a three to four
times longer cell cycle). Insights into how therapeutic
goals might be achieved with such cells have derived
from observations of rodent NSCs, which, by and large,
the hNSCs have mimicked. These shared behaviors likely
reflect a fundamental biology that cuts across species. For
example, hNSCs can participate in CNS development,
including migration from germinal zones along
migratory streams, to widely disseminated CNS
regions.6,28,48,66 They retain a responsiveness to regional
and temporal developmental cues to become multiple cell
types in these regions. Genetically manipulatable ex vivo,
hNSCs in these widely disseminated locations, can
express a retrovirally transduced transgene, offering
promise for future gene therapy applications. Secretory
products from hNSCs can cross-correct genetic metabolic
defects.6 hNSCs can differentiate into neuronal subtypes
that are deficient in mouse mutants,6 suggesting their
potential for cell replacement. hNSCs are drawn to path-
ology (as modeled by brain tumor) from as far as the
opposite side of the adult rodent brain.40 In the contused
adult rat spinal cord, hNSCs (in pilot studies) can yield
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Figure 4 NSCs can express functional genes within a pathological situation (modified from Ref. 40). (a) Bioactive transgene (cytosine deaminase (CD))
remains functional (as assayed by in vitro oncolysis) when expressed within NSCs. CNS-1 glioblastoma cells (red) were co-cultured with CD-transduced
murine NSCs (CD-NSCs) (A, B) (blue). Co-cultures unexposed to 5-fluorocytosine (5-FC) grew healthily and confluent (A), whereas plates exposed to
5-FC showed dramatic loss of tumor cells (B) represented quantitatively by the histograms (∗ = P  0.001).The oncolytic effect was identical whether
1 × 105 CD-NSCs or half that number were co-cultured with a constant number of tumor cells. (In this paradigm, subconfluent NSCs were still mitotic
at the time of 5-FC exposure and thus also subject to self-elimination by the generated 5-FU and its toxic metabolites.) (b) Expression of a bioactive
transgene (CD) delivered by NSCs in vivo as assayed by reduction in tumor mass. The size of an intracranial glioblastoma populated with CD-NSCs
in an adult nude mouse treated with 5-FC was compared with that of tumor treated with 5-FC, but lacking CD-NSCs. These data, standardized against
and expressed as a percentage of a control tumor populated with CD-NSCs receiving no treatment, are presented in the histograms in panel A. These
measurements were derived from measuring the surface area of tumors (like those in Figure 3), representative camera lucidas of which are presented in
panels B–D. Note the large areas of a control non-5-FC-treated tumor containing CD-NSCs (B) and a control 5-FC-treated tumor lacking CD-NSCs
(C) as compared with the dramatically smaller tumor areas of the 5-FC-treated animal who also received CD-NSCs (D) (~80% reduction as per the
histogram in panel A, ∗ = P  0.001), suggesting both activity and specificity of the transgene. The lack of effect of 5-FC on tumor mass when no
CD-bearing NSCs were within the tumor (C) was identical to the effect of CD-NSCs in the tumor without the gene being employed (B).
neurons (including motor neuron-like cells) that can
make long distance connections both rostral (to higher
centers) and caudal to the lesion, have the ability to con-
duct corticospinal signals, and result in apparent func-
tional improvement.
If insights from rodents were applicable to humans,
then experiments with monkeys would provide a neces-
sary intermediate step for ensuring translation of those
insights. hNSCs transplanted into normal fetal Old World
monkeys via intracerebroventricular injections that
allowed the cells access to the VZ, integrated throughout
the developing brain, yielding neurons and glia appropri-
ate to given cortical laminae, as well as contributing to
such secondary germinal zones as the SVZ (that serve
homeostatic and self-repair functions into adulthood).9 It
is worth noting that this intervention could be viewed as
somewhat of a ‘dress rehearsal’ for procedures that are
actually feasible for in utero therapy of human neuro-
genetic disorders. Such prenatal treatments could be
directed not only at congenital disorders but also, theor-
etically, at neurodegenerative diseases that are not
expressed until adulthood or middle age, but whose ante-
natal genetic diagnosis is possible (eg HD).
Pilot experiments have begun involving hNSCs in
lesioned non-human primates – often the primate equiv-
alent of some of the rodent models described above. Such
experiments not only help determine the cells’ safety and
efficacy, but also provide a more direct understanding of
‘human-like’ development and the response of human
stem cells to ‘human-like’ neurodegenerative environ-
ments. They also permit formulation of the logistics of
cell administration to an anatomy more relevant to
humans. For example, analysis of the fate and impact of
hNSCs in the MPTP-induced model of DA depletion and
Parkinsonism in Old World St Kitts African Green Monk-
eys has begun. In encouraging pilot studies, hNSCs
appeared to survive in the SN and some spontaneously
converted to TH+ cells. Improvement in DA activity in
some recipient pilot monkeys (as assessed by SPECT)
might either be the result of DA cell replacement by
NSCs or reflect the provision by NSCs of factors promot-
ing the survival of host DA neurons (as described above
for the mouse), or a function of both. Either mechanism,
if corroborated, will likely be therapeutically important.
The field of NSC biology is at a very early stage of
development. Many of our suggestions are highly specu-
lative, and much needs to be learned about the properties
of such cells. While work is ongoing on the isolation,
propagation, and transplantation of hNSCs, many
important questions need to be addressed experimentally
before using such cells in clinical applications. For
instance, what factors optimize the expansion, stability,
engraftment, migration and differentiation of trans-
planted NSCs? What variables dictate the efficiency of
foreign gene expression by engrafted NSCs? What are the
fundamental pathophysiological needs in a given disease
for reversing progression and/or restoring function?
When is the proper time to administer cells? What are
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derived cells function normally?
Broader implications
With the recent attention paid to embryonic stem cells
(ESCs) and their ability to give rise to neural precur-
sors,29,30,67 with the discovery of stem cells in other solid
organ systems, and with the possibility that some of these
tissue-resident stem cells from other organ systems may
enter the CNS (possibly giving rise to neural elements),
the question arises as to whether these other varieties of
stem cells can also address the global demands of neuro-
logical diseases or will this still be the unique niche for
NSCs. Only future research will determine whether such
other stem cells can meet the gold standard of safety,
efficiency, simplicity and efficacy established by NSCs.
Regardless of how that question is resolved by future
experiments, it seems likely that NSCs have unveiled a
novel therapeutic paradigm that may now be emulated
for other organs. The existence of stem cells in other
organs or the ability of ESCs to give rise to such precur-
sors suggests that stem cell-mediated widespread repair
of those tissues (eg heart, liver, muscle, pancreas, etc)
may similarly be possible in much the same way as NSCs
seem to do for the CNS. The demand for organ donation
may be forestalled, for example. While approaches to dis-
ease have heretofore focused on stopping pathology,
stem cells now allow for the complementary approach of
‘starting over’ – replacing defective components with
more normal ones. The possibility of doing autografts
with stem cells derived from an adult remains contro-
versial, particularly for genetic diseases. The cells derived
from an individual with a genetic impairment likely
already harbor that genetic defect or predisposition and
may not be useful or effective.
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